| 0.7836 -0.005 (-0.66%) | 01-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.99 | 1-year : | 1.22 |
| Resists | First : | 0.85 | Second : | 1.04 |
| Pivot price | 0.73  |
|||
| Supports | First : | 0.52 | Second : | 0.44 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.71 |
| MA(100) : | 0.79 |
MA(250) : | 0.83 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.3 |
D(3) : | 57.6 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 1.58 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COSM ] has closed below upper band by 37.6%. Bollinger Bands are 62.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.82 | 0.82 - 0.82 |
| Low: | 0.74 - 0.75 | 0.75 - 0.75 |
| Close: | 0.78 - 0.78 | 0.78 - 0.79 |
Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Thu, 23 Jan 2025
Cosmos Health expands distribution of Avian Influenza kits - MSN
Thu, 23 Jan 2025
Cosmos Health Expands Virax PCR Kit Distribution to Saudi Arabia, UAE in Major Gulf Growth - StockTitan
Wed, 22 Jan 2025
Cosmos Health Secures Rights to Breakthrough Cancer Drug Patents Valued at $24.6M - StockTitan
Tue, 21 Jan 2025
Cosmos Health CEO Shows Conviction With $425,000 Share Purchase, Total Investment Tops $17M - StockTitan
Sun, 19 Jan 2025
Cosmos health CEO Siokas acquires shares in $40,000 debt exchange - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 23 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 364 (K) |
| Shares Short P.Month | 652 (K) |
| EPS | -2.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.26 |
| Profit Margin | -38.2 % |
| Operating Margin | -19 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -56.7 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.42 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0.32 |
| Price to Cash Flow | -2.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|